

General information

Ticker	NYSE:ABBV
Company	AbbVie Inc.
Industry	Healthcare
Primary	Pharmaceuticals

Price chart

Actual price:	60.5	Avg. price 3Y:	50.2
52-week low:	46.5	Avg. price 5Y:	50.2
52-week high:	69.7	Avg. price 10Y:	50.2

AbbVie recently consolidated c. -20% from its 52-week high at 69.7 USD to approx. USD 56 which is slightly below its 200 day MA. AbbVie underperformed the S&P 500 by 12.6% in the last 3 month, albeit performing in line with S&P 500 in the last 12 month. RSI indicates oversold territory at the current price of USD 56 passing my investment criteria 7.

Dividend Yield & Payout Ratio

Actual yield:	3.4%	Avg. yield 5Y:	3.4%
Target yield:	3.5%	Div. CAGR 5Y:	0.0%
Payout ratio:	150%	Chowder Rule:	3.4%

At 56.50 USD price (11.03.2015) attractive dividend yield of 3.6%, above target yield of 3.5%. 2yrs of dividend streak after spin-off compares to 42 years when ABBV belonged to Abbott Labs. Dividend growth commitment and USD 5bn share buyback program. FY14 payout ratio at 158% however, for FY15 a payout of 48% is expeted. Chowder score is 16.5%, with 2yr Div CAGR of 12.9% + 3.6% yield . All growth metrics PASSED.

Valuation (FY1 EV/EBITDA)

Actual FY1 EV/EBITDA:	10.3x
Avg. FY1 EV/EBITDA 5Y:	10.8x
Avg. FY1 EV/EBITDA 10Y:	10.8x

FY1 EBITDA valuation is volatile recently potentially resulting from changes in analyst estimates (FY1). I consider a FY1 EBITDA of 5.0x as fair value, which XOM did not pass, however, was pretty close. XOM's current EV/EBITDA however, has coming down in line with the drop in stock price to 5.2x, which is c. in line with ist 5-year valuation average. Given that, I can justify a buy.





Valuation (FY1 P/E)

Actual FY1 P/E:	14.0x
Avg. FY1 P/E 5Y:	15.0x
Avg. FY1 P/E 10Y:	15.0x

Due to the trailing nature of P/E ratio calculation P/E diverges from FY1 P/E – as above – as FY14 results became immanent. Based on Mgmt guidance of 4.05-4.25 USD EPS in 2015, FY1 P/E declined with the declining stock price. The result was a FY1 P/E at c. 13.0x (11.03.2015), 2.0x below its average valuation level of 15.0x, signaling a PASS for my valuation criteria.

Fulfillment of investment criteria

1. Dividends streak	FAIL	5. Growth	PASS
2. Price / Yield	PASS	6. Valuation	PASS
3. Chowder Score	PASS	7. RSI	PASS
4. Payout ratio	FAIL		



DISCLAIMER: The information provided hereby should be viewed for educational and/or entertainment purposes only. Data provided is from a reliable source, but its correctness cannot be guaranteed by the author. This document does not represent a recommendation to buy or sell stocks. The germandividendinvestor is not liable for any losses suffered by any parties in particular when contributing funds to stocks that are subject of discussions. Investments are subject to price fluctuations and brokerage fees that can lead to substantial losses. Please consult with an investment professional and/or tax professional before investing any of your money.